健友股份(603707.SH):米力農注射液獲批上市
格隆匯6月23日丨健友股份(603707.SH)公吿,公司於近日收到國家藥品監督管理局關於核准簽發米力農注射液(規格:10ml:10mg;20ml:20mg;50ml:50mg)藥品註冊證書的通知,公司的米力農注射液符合藥品註冊的有關要求,獲批註冊,取得藥品註冊證書。
米力農是一種磷酸二酯酶抑制劑類強心藥,有擴張血管平滑肌的作用,能降低心臟負荷,還能極好地改善腎臟和肌肉供血,臨牀用於急性失代償性心力衰竭患者的短期靜脈治療。
公司米力農注射液獲得國家藥監局的藥品註冊證書,標誌着公司具備了在國內市場銷售該藥品的資格,進一步豐富了公司的產品線,有助於提升公司產品的市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.